---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-026802"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:28:10.250921+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Oncocyte appoints James Liu as Controller & Principal Accounting Officer

## Summary
- James Liu, 27, appointed Controller & Principal Accounting Officer effective Sept 20, 2022.
- Liu previously served as Interim Controller since July 2022 and as Manager of SEC Reporting & Compliance.
- Annual salary of $175,000; eligible for discretionary annual bonus with target of 30% of base salary.
- Receives one-time grant of 75,000 stock options vesting 25% after 1 year, then monthly over 3 years.
- No family relationships or related party transactions with the company's directors or officers.

## SEC filing metadata
- accession: 0001493152-22-026802
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222026802/0001493152-22-026802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222026802/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-026802
- JSON: https://secwatch.observer/filing/0001493152-22-026802.json
- Plain text: https://secwatch.observer/filing/0001493152-22-026802.txt

## Key facts
- Executive change
  James Liu was appointed as Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Controller & Principal Accounting Officer
  source text: Effective September 20, 2022, Oncocyte Corporation (“Oncocyte” or the “Company”) appointed James Liu as the Company’s Controller & Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222026802/0001493152-22-026802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.